tradmap

TVGN Earnings Tevogen Bio Holdings Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$8 -$4 $0 2023 2024 2025
EPS
Net income (annual)
-$60M -$28M $4M $0 2022 2023 2024 2025
Net income
Return on equity (annual)
-13% 153% 319% 0% 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$5 -$2 $0 Q1 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$10M $448891 $11M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-194% -26% 142% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–15 of 15
Q2 20262026-06-30-3.162026-08-1410-Q
Q1 20262026-03-31-1.612026-05-1510-Q
FY 20252025-12-31-8.082026-03-3110-K
Q3 20252025-09-30-0.122025-11-1410-Q
Q2 20262025-06-30-4.952026-08-1410-Q
Q1 20262025-03-31-3.252026-05-1510-Q
FY 20252024-12-31-3.502026-03-3110-K
Q3 20252024-09-30-0.012025-11-1410-Q
Q2 20252024-06-30-0.292025-08-1410-Q
Q1 20252024-03-31-0.262025-05-1410-Q
FY 20242023-12-31-2.442025-04-0210-K
Q3 20242023-09-30-2.302024-11-1910-Q
Q2 20242023-06-30-0.442024-08-1410-Q
Q1 20242023-03-31-0.262024-05-2810-Q
Q1 20232022-03-310.002023-05-2210-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.